RCKT Q4 2025 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$44M

Net Income

-$43M

EPS (Diluted)

$-0.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$330M

Total Liabilities

$53M

Stockholders' Equity

$277M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$44M	-$63M	+29.9%
Net Income	-$43M	-$60M	+29.5%